Slika na naslovnici

New orally active anticoagulant agents for the prevention and treatment of venous thromboembolism in cancer patients

Grigoris T Gerotziafas,1,2 Isabelle Mahé,3 Ismail Elalamy1,21Service d'Hématologie Biologique, Hôpital Tenon, Hôpitaux Universitaires Est Parisien Assistance Publique Hôpitaux de Paris, Paris, France; 2ER2UPMC, Faculté de M&e...

Shranjeno v:

Bibliografske podrobnosti
Main Authors:	Gerotziafas GT (Author), Mahé I (Author), Elalamy I (Author)
Format:	Knjiga
Izdano:	Dove Medical Press, 2014-06-01T00:00:00Z.
Teme:	article
Online dostop:	Connect to this object online.
Oznake:	Označite Brez oznak, prvi označite!

Podobne knjige/članki

New anticoagulants for the prevention of venous thromboembolism
od: Cecilia Becattini, et al.
Izdano: (2010)

Cost-effectiveness of new oral anticoagulants in the treatment and secondary prevention of venous thromboembolism
od: A. V. Rudakova
Izdano: (2015)

Cost-effectiveness of new oral anticoagulants in the treatment and secondary prevention of venous thromboembolism
od: A. V. Rudakova
Izdano: (2015)

New Oral Anticoagulants Open New Horizons for Cancer Patients with Venous Thromboembolism
od: Wumaier K, et al.
Izdano: (2022)

The Current Status of Direct Oral Anticoagulants in Cancer-Related Venous Thromboembolism Treatment
od: К. V. Lobastov, et al.
Izdano: (2020)

The current place of direct oral anticoagulants in the prevention/treatment of venous thromboembolism
od: Tomić Maja
Izdano: (2020)

Efficacy and safety of the new oral anticoagulants in the treatment of venous thromboembolic complications: meta-analysis
od: V. I. Petrov, et al.
Izdano: (2017)

Efficacy and safety of the new oral anticoagulants in the treatment of venous thromboembolic complications: meta-analysis
od: V. I. Petrov, et al.
Izdano: (2016)

Efficacy and safety of the new oral anticoagulants in the treatment of venous thromboembolic complications: meta-analysis
od: V. I. Petrov, et al.
Izdano: (2017)

CURRENT TREATMENT OF VENOUS THROMBOEMBOLIC COMPLICATIONS WITH ANTICOAGULANTS: APIXABAN
od: I. S. Yavelov
Izdano: (2015)

The New Oral Anticoagulants for the Treatment of Venous Thromboembolism: A New Paradigm Shift in Antithrombotic Therapy
od: Taki Galanis, MD, et al.
Izdano: (2014)

EFFICACY AND SAFETY OF THE ORAL ANTICOAGULANTS IN THE MANAGEMENT OF VENOUS THROMBOEMBOLISM: INDIRECT COMPARISON
od: V. I. Petrov, et al.
Izdano: (2016)

Anticoagulant therapy for acute venous thromboembolism
od: Hilal Ermiş, et al.
Izdano: (2017)

Non-vitamin K oral anticoagulant in the prevention and treatment of venous thromboembolism. Why betrixaban is different?
od: Łukasz Wołowiec, et al.
Izdano: (2017)

Non-vitamin K oral anticoagulant in the prevention and treatment of venous thromboembolism. Why betrixaban is different?
od: Łukasz Wołowiec, et al.
Izdano: (2017)

Use of novel oral anticoagulants for the treatment of venous thromboembolism and its considerations in Asian patients
od: Lee YJ
Izdano: (2014)

Assessment of direct-acting oral anticoagulants for the treatment of venous thromboembolism in cancer patients in Thai Tertiary Care Hospital
od: Jennis Meanwatthana, et al.
Izdano: (2022)

Efficacy and safety of novel oral anticoagulants versus vitamin K antagonists in the treatment of venous thromboembolism
od: Maodi Xu, et al.
Izdano: (2018)

Oral anticoagulants for the treatment of venous thromboembolism and non-valvular atrial fibrillation: a cost analysis
od: Isabella C DENARDIN, et al.
Izdano: (2021)

Direct oral anticoagulants in pediatric venous thromboembolism: Review of approved products rivaroxaban and dabigatran
od: Maha Al-Ghafry, et al.
Izdano: (2022)

Underutilization of Anticoagulant for Venous Thromboembolism Prophylaxis in Three Hospitals in Jakarta
od: T. Djumhana Atmakusuma, et al.
Izdano: (2016)

Efficacy and safety of direct oral anticoagulants for preventing venous thromboembolism in hospitalized cancer patients: a national multicenter retrospective cohort study
od: Shuyi Wu, et al.
Izdano: (2024)

Clinical Benefits of Oral Anticoagulant Use in Cancer Patients at Increased Risk for Venous Thromboembolism per Khorana Index
od: Choi YJ, et al.
Izdano: (2021)

PREVENTION OF VENOUS THROMBOEMBOLIC EVENTS IN PATIENTS WITH CANCER
od: Ju. A. Fedotkina
Izdano: (2019)

Prevention, diagnosis and treatment of venous thromboembolism
od: Dominik Machaj, et al.
Izdano: (2020)

Prevention and Treatment of Venous Thromboembolism in Pregnancy
od: Erna Suparman
Izdano: (2022)

New Oral Anticoagulants for Venous Thromboembolism Prophylaxis in Total Hip and Knee Arthroplasty: A Systematic Review and Network Meta-Analysis
od: Yi-hu Yi, et al.
Izdano: (2022)

Safety of discontinuation of anticoagulants after venous thromboembolism: whether D-dimer level should be taken into account?
od: I. S. Yavelov
Izdano: (2023)

Modern approaches to the prevention of venous thromboembolic complications in patients with active cancer
od: Yu. A. Fedotkina, et al.
Izdano: (2023)

Cost-effectiveness analysis of direct oral anticoagulants versus low-molecular-weight heparin and no thromboprophylaxis in primary prevention of cancer-associated venous thromboembolism in China
od: Yue Wu, et al.
Izdano: (2024)

Comparative effectiveness and safety of direct oral anticoagulants versus warfarin among patients with recurrent venous thromboembolism
od: Hye‐Rim Kang, et al.
Izdano: (2023)

Cost-Effectiveness Analysis of Direct Oral Anticoagulants Versus Vitamin K Antagonists for Venous Thromboembolism in China
od: Ke-Xin Sun, et al.
Izdano: (2021)

Predictors of Direct Oral Anticoagulants Utilization for Thromboembolism Prevention in Atrial Fibrillation
od: Caroline Brais, et al.
Izdano: (2017)

New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events
od: Mekaj YH, et al.
Izdano: (2015)

Dealing with thrombocytopenia during anticoagulation with heparins for active venous thromboembolism: a play-it-safe practical approach
od: Abdel-Razeq H, et al.
Izdano: (2011)

A Cross-sectional Study of the Assessment of Venous Thromboembolism Risk and Use of Anticoagulant Thromboprophylaxis
od: Emile Abimana, et al.
Izdano: (2022)

Comparative effectiveness and safety of extended anticoagulant therapy among Medicare beneficiaries with venous thromboembolism
od: Haesuk Park, et al.
Izdano: (2023)

Possibility to use direct oral anticoagulants to prevent thromboembolic events in patients with COVID-19
od: V. A. Otdelenov, et al.
Izdano: (2020)

Oral anticoagulants in the prevention of thromboembolic complications in cardiac patients: analysis of use in the Russian Federation
od: A. A. Gruzdeva, et al.
Izdano: (2020)

Preeclampsia and venous thromboembolism
od: K. N. Grigoreva, et al.
Izdano: (2022)